Ipsen SA - Company Profile
Powered by 
All the data and insights you need on Ipsen SA in one report.
$295
- Save hours of research time and resources with
our up-to-date Ipsen SA Strategy Report
- Understand Ipsen SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ipsen SA (Ipsen) is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases, and neurological diseases, including specialty pharmaceutical products. The company develops and commercializes novel medicines for cancer, neuroscience and rare diseases and offers products to treat gastrointestinal disorders, and neurodegenerative pathologies. Ipsen sells its drugs through a network of distributors and directly to hospitals in a few countries. The company operates its research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, and rest of the world. Ipsen is headquartered in Paris, France.
Headquarters
France
Address
65 Quai Georges Gorse, Boulogne-Billancourt, Bourgogne, 92100
Website
www.ipsen.com
Telephone
33 1 58335000
No of Employees
5,072
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IPN (EPA)
Revenue (2022)
$3.6B
4.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-0.6%
(2022 vs 2021)
Market Cap*
$9.8B
Net Profit Margin (2022)
XYZ
-5.2%
(2022 vs 2021)
* As of and is in US$
Ipsen SA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Specialty Care: | Somatuline |
| Oncology - | Decapeptyl |
| Renal Cell Carcinoma | Hexvix |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In February, the company received approval from the US Food and Drug Administration for the supplemental new drug application for the Onivyde (irinotecan liposome injection) combination regimen (NALIRIFOX) to treat metastatic pancreatic adenocarcinoma (mPDAC) in adults. |
| 2023 | Regulatory Approval | In August, the company received approval from the US FDA for its Sohonos (palovarotene) capsules to treat people with the ultra-rare bone disease, fibrodysplasia ossificans progressiva. |
| 2023 | Contracts/Agreements | In June, the company entered an agreement with Medetia to accelerate the development of next-generation solutions for rare diseases. |
Competitor Comparison
| Key Parameters | Ipsen SA | Merck & Co Inc | Pfizer Inc | Bayer AG | Sanofi |
|---|---|---|---|---|---|
| Headquarters | France | United States of America | United States of America | Germany | France |
| City | Boulogne-Billancourt | Kenilworth | New York | Leverkusen | Paris |
| State/Province | Bourgogne | New Jersey | New York | Nordrhein-Westfalen | Ile-de-France |
| No. of Employees | 5,072 | 72,000 | 88,000 | 99,723 | 87,994 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Marc de Garidel | Chairman | Executive Board | 2016 | 65 |
| David Loew | Chief Executive Officer; Director | Executive Board | 2020 | 56 |
| Aymeric Le Chatelier | Chief Financial Officer; Executive Vice President | Senior Management | 2020 | - |
| Sandra Silvestri, M.D. | Executive Vice President; Head - Global Medical Affairs, Patient Safety and Patient Affairs; Chief Medical Officer | Senior Management | 2023 | - |
| Philippe Lopes Fernandes | Chief Business Officer; Executive Vice President | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward